Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,766 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,441 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,353)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00235560 | Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients(LAM-RAPA) | completed | Phase 2 | 50 | University Hospital, ToulouseOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03379727 | Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. | completed | Phase 3 | 301 | Novartis Pharmaceuticals |
| 15 |
| Feb 29, 2024 |
| clinicaltrials |
| NCT05845827 | Dietary Impact on Continuous Glucose Monitoring | completed | — | 30 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03720366 | A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients | completed | Phase 1 | 40 | CelgeneINDUSTRY | 2 | Feb 28, 2024 | clinicaltrials |
| NCT02013648 | Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) | completed | Phase 3 | 204 | University of UlmOTHER | 2 | Feb 23, 2024 | clinicaltrials |
| NCT02441803 | Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT03335267 | Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia | completed | Phase 2 | 30 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT03564288 | Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 14 | Oscotec Inc.INDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02222272 | Effect of 2nd Gen TKI in CML | completed | — | 432 | European Society for Blood and Marrow TransplantationNETWORK | 9 | Feb 20, 2024 | clinicaltrials |
| NCT04964908 | Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia(CREEK) | completed | — | 1,088 | AstraZenecaINDUSTRY | 17 | Feb 20, 2024 | clinicaltrials |
| NCT06267898 | Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML | completed | — | 222 | European Society for Blood and Marrow TransplantationNETWORK | 3 | Feb 20, 2024 | clinicaltrials |
| NCT00577278 | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | completed | Phase 2 | 41 | City of Hope Medical CenterOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT01812252 | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant(ICT-HCT) | completed | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03996096 | Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.(KIWIS) | completed | — | 50 | University Hospital, CaenOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT02168140 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 | 16 | Wake Forest University Health SciencesOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT02435849 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients(ELIANA) | completed | Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 11 | Feb 13, 2024 | clinicaltrials |
| NCT03964259 | Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 | 10 | Virginia Commonwealth UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04169022 | AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells(CAR-LAM) | completed | N/A | 86 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04887857 | A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)(OMNIVERSE) | completed | Phase 1 | 6 | CelgeneINDUSTRY | 2 | Feb 12, 2024 | clinicaltrials |
| NCT01802814 | International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 | completed | Phase 3 | 700 | Charite University, Berlin, GermanyOTHER | 17 | Feb 9, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT02057185 | Occupational Status and Hematological Disease(EMATO0113) | completed | — | 141 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04825548 | Post-thrombotic Syndrome After Deep Venous Thrombosis (DVT) in Patients Treated According to the NOPHO ALL2008 Protocol | completed | — | 27 | Aarhus University HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04843150 | Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase -An ALLTogether Pilot Study | completed | — | 320 | Aarhus University HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04843514 | TDM of Asparaginase in ALL2008 | completed | — | 765 | Aarhus University HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04858568 | Immune Responses to COVID-19 Vaccination in Lymphoma Patients(PROSECO) | completed | — | 592 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03672695 | Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia. | completed | Phase 1 | 37 | Institut de Recherches Internationales ServierOTHER | 3 | Feb 5, 2024 | clinicaltrials |
| NCT02473146 | Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4(ALFA1401) | completed | Phase 2 / Phase 3 | 225 | Versailles HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT01041508 | Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia. | completed | Phase 1 | 18 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT01497002 | Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a(AML2004) | completed | Phase 3 | 1,222 | University of LeipzigOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05560412 | Zein Nanoparticles for Glycemic Control(GLUCOCAPS) | completed | N/A | 69 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01522469 | Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations | completed | Phase 2 | 14 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05209360 | Heel Wedges and Carbon Fiber Custom Dynamic Orthoses to Control Knee Biomechanics(CDOKNEEpilot) | completed | N/A | 20 | University of IowaOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT01904136 | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04744818 | Effects of Iron Supplementation on Pediatric Vaccine Response(VINO) | completed | N/A | 288 | Jessica RiguttoOTHER | 2 | Jan 24, 2024 | clinicaltrials |
| NCT05973032 | MRD Detection by NGS in Pediatric B-ALL | completed | — | 430 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT02663622 | Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) | completed | Phase 2 | 44 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03574012 | SmART Heart: Study of mHealth Apps to Reduce Cancer-Treatment Effects on the Heart | completed | N/A | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02367456 | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients(BRIGHT 1012) | completed | Phase 1 | 73 | PfizerINDUSTRY | 6 | Jan 19, 2024 | clinicaltrials |
| NCT02461537 | Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML(ETAL3-ASAP) | completed | Phase 3 | 281 | DKMS gemeinnützige GmbHOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT06211452 | Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia | completed | Phase 3 | 258 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT02385110 | Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05939791 | Physical Exercise and Dairy Probiotics in Childhood Cancer Survivors(Exerbioall) | completed | N/A | 29 | Comenius UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03833180 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | completed | Phase 1 | 91 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04474678 | Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") | completed | N/A | 240 | Medical University of ViennaOTHER | 4 | Jan 9, 2024 | clinicaltrials |
| NCT05045443 | Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia(CurcumPedALL) | completed | Phase 2 | 30 | Ain Shams UniversityOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06195735 | Forecasting Hypersensitivity Against PEG-asparaginase to Optimize Outcome in ALL | completed | — | 649 | Aarhus University HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04956666 | A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)(ALL) | completed | Phase 2 | 75 | Institut de Recherches Internationales ServierOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT02789254 | FLYSYN in MRD Positive AML(FLYSYN-101) | completed | Phase 1 / Phase 2 | 31 | Synimmune GmbHINDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Feb 29, 2024source: clinicaltrials